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1. Introduction 
The history of Mycobacterium tuberculosis (MTB) as the main agent of tuberculosis (TB) goes 
back a very long time. Fragments of the spinal column of Egyptian mummies from 2400 BCE 
(Before Common Era) show definite pathological signs of tubercular decay (Tripathi, Tewari 
et al., 2005). From that time to the present day millions have died of the disease and only a 
few drugs are active against the bacilli. Current data show an ancient disease more 
prevalent in the world today than at any other time in human history (Koul, Arnoult et al., 
2011). Annually, TB is responsible for the death of two to three million people worldwide 
and global economic losses around $ 12 billion (Ma, Lienhardt et al., 2010). Approximately a 
third of the world’s population is estimated to be infected with MTB, giving rise to 9.4 
million new cases of active TB disease each year (Zwerling, Behr et al., 2011). In addition, the 
highly resistant Multi-Drug-resistant (MDR) and Extensively-Drug-Resistant (XDR) MTB 
organisms are virtually untreatable in immunocompetent patients. So when these bacteria 
enter into contact with highly immunocompromised HIV-infected populations, the 
mortality rate reaches 100% within a few weeks of infection (Gandhi, Nunn et al., 2010).  
No new specific drug against MTB has been developed since 1960 and the emergence of MDR-
TB and XDR-TB highlights the ineffectiveness of current treatment (Lalloo e Ambaram, 2010). 
An effective new drug against TB could: (i) reduce the duration of the treatment, (ii) be active 
against resistant strains, (iii) not interfere with antiretroviral drugs and (iv) be active against 
latent bacilli (Ma, Lienhardt et al., 2010). According to Koul et al (2011), the key questions are: 
how vigorous are current strategies to discover new TB drugs and what measures could be 
taken to shorten the protracted clinical development of new drugs (Koul, Arnoult et al., 2011). 
In this chapter we describe a successfully working pipeline being developed at the “Dr. 
Hugo David” Laboratory, which is based on the responses that a new drug has to provide, 
ordered into a sequence of lead-optimization stages that go from initial screening hits to the 
final in vitro and in vivo preclinical assays of candidate drugs. 
2. Rational pipeline: Phenotypic or genotypic? 
The lack of new anti-TB drugs since 1960, when rifampicin (RMP) was added to the 
therapeutic together with the failure of current treatment against MDR and XDR-TB and  
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some new public and private investments, have caused an explosion and awakening of 
many research groups, to develop new strategies to identify new drugs against TB. This 
research follows two different paths, phenotypic and genotypic, both concerned with the 
discovery of new drugs and the development of new rapid, inexpensive and reproducible 
assays. 
Owing to the availability of the genome sequence of MTB (Cole, Brosch et al., 1998), the 
pharmaceutical companies and research institutions have been driven to employ target-
based high-throughput assays for the identification of candidate TB drugs. However, the 
genome- derived target-based approaches have had little success in the antibacterial 
therapeutic area in general (Payne, Gwynn et al., 2007; Koul, Arnoult et al., 2011). One of the 
most important targets investigated in the search for new drugs against TB is the group of 
isocitrate lyases. These enzymes are the key to the glyoxylate-shunt pathway and are 
essential to the intracellular growth of mycobacteria and their long-term persistence in mice. 
However, the several high-throughput screening campaigns launched to identify inhibitors 
of isocitrate lyases were discontinued, owing to their lack of druggability (WGND, 2011). 
Even when a good bacterial enzyme inhibitor is found, the question of whether it can be 
converted into a compound that can easily penetrate the highly impermeable mycobacterial 
cell wall still has to be answered. 
With regard to phenotypic assays, at first, new drugs were discovered by randomly testing 
compounds on whole cells. This strategy identified all the compounds currently employed 
in first-line therapy, namely, RMP, isoniazid (INH), pyrazinamide (PZA) and ethambutol 
(EMB) (Handbook of anti-tuberculosis agents, 2008).  
Nowadays, five drugs are undergoing clinical trials: SQ-109 (Sequella Inc.), OPC-67583 
(Otsuka Pharmaceutical Company), LL3858 (Lupin Ltd), TMC 207 (Johnson & Johnson) and 
PA-824 (TB Alliance and Novartis) (Lalloo e Ambaram, 2010; Lienhardt, Vernon et al., 2010) 
were identified by the whole-cell-screening approach, suggesting that the screening strategy 
based on whole cells is much more successful than targeting single enzymes (Koul, Arnoult 
et al., 2011). 
3. “Hugo David” research laboratory pipeline 
The main control and research organizations on neglected diseases in the world (Global 
Alliance, National Institutes of Health and World Health Organization) suggest several 
whole-cell biological assays involving in vitro and in vivo approaches to explore all the 
features that the new drug must possess, in order to control the disease (Orme, Secrist et al., 
2001; Ma, Lienhardt et al., 2010; Koul, Arnoult et al., 2011). On the basis of those suggestions, 
for more than 10 years, the Mycobacteriology Laboratory of the School of Pharmaceutical 
Sciences, State University of São Paulo (UNESP), in association with many chemical 
laboratories around the world, has been seeking new drugs from natural products or 
synthetic compounds, both organic and inorganic (Do Nascimento, Von Poelhsitz et al., 
2008; Higuchi, Pavan et al., 2008; Maia, Pavan et al., 2009; Moro, Mauro et al., 2009; Pavan, 
Leite et al., 2009; Pavan, Sato et al., 2009; Pavan, 2009; Santos, Yamasaki et al., 2009; Silva, 
Martins et al., 2009; Carli, Quilles et al., 2010; Honda, Pavan et al., 2010; Maia, Graminha et al., 
2010; Pavan, Maia et al., 2010; Pavan, Von Poelhsitz et al., 2010; Tarallo, Urquiola et al., 2010; 
Miyata, Pavan et al., 2011). While screening over 2,000 compounds, we discovered 
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promising candidates (“hits”) based on MIC values and other biological assays were added 
to select the lead compounds. After years of investigation, it was possible to assemble a 
rapid and inexpensive pipeline, to organize the search for new drugs against TB, from 
screening to the in vivo preclinical phase. The pipeline developed in parallel with the 
promising results for the lead compounds and out of a need to understand better their 
biological characteristics. By application of this pipeline, we now have some very promising 
compounds containing ruthenium complexes that exhibit a MIC (Minimum Inhibitory 
Concentration) comparable to or better than first-line drugs, low cytotoxicity and a 
selectivity index (SI) much higher than 10 (Do Nascimento, Von Poelhsitz et al., 2008; Pavan, 
Von Poelhsitz et al., 2010). 
The rational phenotypic pipeline mounted in this laboratory is outlined in the flowchart in 
Figure 1. This pipeline is divided into 3 stages: Screening, in vitro preclinical and in vivo pre-
clinical. 
Screening: First of all, the MIC of the putative drug compound against MTB H37Rv ATCC 
27294 is estimated by the Resazurin Microtiter Assay (REMA) (Palomino, Martin et al., 2002). 
Compounds with anti-MTB activity at ≤ 10 µg/mL (or molar equivalent) are selected for the 
next step, which is to test their cytotoxicity (IC50) on J774A.1 (ATCC TIB67) macrophage 
cells, HepG2 (ATCC HB 8065) hepatic cells and VERO (ATCC CCL81) normal cells, as 
described by Pavan et al. (2010) (Pavan, Maia et al., 2010). The last screening step is to 
evaluate the therapeutic safety of the compound for in vivo assays, by calculating the SI, 
which is the ratio of IC50 to MIC (Orme, Secrist et al., 2001). Compounds with SI ≥ 10 are 
selected for the next stage. 
In vitro Pre-Clinical Stage: At this stage, the first step is to test if the compounds can act on 
recombinant MTB Erdman (ATCC 35801) bacteria containing the luciferase plasmid (pFCA-
luxAB), inside infected J774A.1 macrophage cells (Snewin, Gares et al., 1999; Pavan, 2009) 
(Figure 2). In the next step of the pipeline, the compounds are tested on clinical isolates with 
a phenotypic and genotypic profile of resistance to INH and RMP already verified (Miyata, 
Pavan et al., 2011), by REMA (Palomino, Martin et al., 2002). This assay allows possible cross 
resistance between the new compounds and the bacteria resistant to INH and RMP to be 
revealed, throwing indirect light on the mechanism of action or target of the new 
compounds. After these assays, interactions between the new compounds and the drugs 
used in current therapy are assessed. Nowadays, TB treatment is based on fixed combined 
doses of RMP, INH, EMB and PZA in the first two months and RMP and INH in the 
following four months (Conde, De Melo et al., 2009). Any new drug must be used in 
combination with other drugs to avoid the appearance of resistant strains. In line with these 
concepts, the interactions between the new compounds and the current anti-TB drugs are 
assessed through the 2D Checkerboard experimental design (Moody, 1992; Luna-Herrera, 
Costa et al., 2007) (Figure 3). Next, the compounds are tested for their ability to inhibit 
dormant bacilli. The Wayne Model (Wayne, 1994) is used to induce the latency stage of the 
recombinant MTB H37Rv (ATCC 2794) (pFCA-luxAB) and the Low Oxygen Recovery Assay 
(LORA) to determine the activity of the new compounds against dormant bacilli (Cho, Warit 
et al., 2007). This assay is important for the discovery of new drugs to use in the control and 
eradication of TB, owing to the ability of MTB to remain dormant in the individual for 
months or years in a state of latency (Wayne, 1994; Ma, Lienhardt et al., 2010). 
Approximately one-third of the world’s population is estimated to be infected with latent  
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Fig. 2. In vitro infection model: a, b, c – Different compounds tested in duplicate and at three 
different concentrations on cells infected with MTB (ATCC 27294) containing the luciferase 
plasmid (pFCA-luxAB); T0 – Initial Control: After the macrophage infection, the cells were 
lysed to confirm the infection; TF – Final Control: Cells only infected with MTB; Negative 
sign: Only uninfected cells. 
 
Fig. 3. 2D Checkerboard: FIC index = (MIC [A] + MIC [B]) combination/(MIC [A] + MIC 
[B]) alone = ≤ 0.75 synergy; 0.75-4 no interaction or > 4 antagonism. Black circle, example of 
lower FIC. Resazurin assay: pink=growth, blue=no growth.  
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bacteria and there are no active drugs against these dormant bacteria. Following this, the 
spectra of activity of new compounds against various microorganisms: Staphylococcus 
aureus (as a gram-positive organism), Escherichia coli (as a gram-negative), Candida albicans 
(as a fungus) and other mycobacterial species (M. avium and M. smegmatis) are assessed 
(Moody, 1992). The last step in this stage is to investigate the in vitro mutagenic capacity 
of the compounds via the AMES test (Maron e Ames, 1983). This assay is important as it 
indicates whether the compound might act as a carcinogen. At the same time the direct 
mechanism or target of the compounds will be investigated by the genotypic 
Representational Difference Analysis method (Lisitsyn e Wigler, 1993; Pastorian, Hawel et 
al., 2000). This assay identifies the genes that are differentially expressed after exposure of 
MTB to the compounds. 
In vivo Pre-Clinical Stage: In the first in vivo test, the therapeutic safety margin is 
determined in accordance with the OECD (Organization for Economic Co-Operation 
Development) guideline, by finding the classical acute toxicity (LD50)  to mice of a single oral 
dose (gavage) of the compounds (OECD, 2001). Next, the in vivo mutagenic potential of the 
compounds should be assessed by the micronucleus assay (Hayashi, Morita et al., 1990). If 
the result is satisfactory, the next step is to understand the pharmacokinetic properties of the 
compounds. To this end, the oral bioavailability of the compounds is determined (Gruppo, 
Johnson et al., 2006) (Figure 4). This assay allows the quantity of the compound that can be  
 
Fig. 4. Oral bioavailability sample collection: (a) C57BL/6 mouse held in a retainer to cut 
the tail and collect blood; (b) Blood dripping from the tail near the Bunsen burner to enable 
dilatation of vein and sterilize air. 
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absorbed into the body of the animal to be measured, as well as its permanence (time of 
degradation) during animal testing. Compounds that give favorable results are then tested 
for their safety (chronic toxicity) in animal models, noting the levels of tolerance when they 
are administered daily for a period at sublethal doses. Finally, the animals are infected 
intranasally with MTB Erdmann (ATCC 35801) (Pethe, Sequeira et al., 2010) and, after 
confirmation of lung infection, they are subjected to oral treatment with the new compounds 
for two weeks and then tested for reduction of the bacterial load in the lungs by cultivation 
of the viable bacilli in the lungs (Falzari, Zhu et al., 2005). This experiment would reveal the 
compounds that effectively reach the lungs and remain these long enough to act on MTB 
internalized in the alveolar macrophages. 
4. Conclusion 
Many groups are working towards the same goal, to find a new drug against TB, not only to 
serve the interests of the pharmaceutical industry, but also prioritizing the patient, 
remembering that the less privileged population is most affected by the disease. The 
question is how to discover new drugs. Here we have described a successfully implemented 
phenotypic pipeline evolved at the “Hugo David” Research Laboratory. 
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